onabotulinum toxin type a
PreclinicalSmall molecule
onabotulinum toxin type a is one of 23 small molecule programs targeting Overactive Bladder. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Myrbetriq
AstellasApproved
Vesicare
AstellasApproved
Enablex
AbbVieApproved
Detrol La
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Toviaz
PfizerApproved
Flomax
SanofiApproved
Cialis
Eli LillyApproved
Oxytrol
WWim Janssens
Approved
Levitra
BayerApproved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for onabotulinum toxin type a. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSouthern Illinois University